The Section is the statistical and data management component of the Center for Cancer Research (CCR). The Section provides statistical leadership and data management consultation for major activities of the Center, and is involved in the design, conduct, monitoring, and statistical analyses of intramural and national multicenter clinical trials of experimental treatments for cancer, and intramural clinical trials for treatment of AIDS. Other major collaborative efforts include studies to identify important prognostic and treatment selection factors, evaluate diagnostic procedures, develop improved staging systems, and assist investigators in the design, execution, and analyses of major in vitro drug testing studies. The Section develops and implements new statistical designs and biometric methods related to the development and evaluation of new cancer and AIDS treatments. The Section maintains computerized data collection systems for intramural and national multicenter clinical protocols, and it works closely with interested branches to improve data recording and retrieval. The Section maintains a unified system for tracking basic information on all patients registered on CCR treatment protocols. Approximately 15% of the Section's activities are HIV-AIDS related.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007202-18
Application #
6558385
Study Section
(BDMS)
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Nakata, Hirotomo; Steinberg, Seth M; Koh, Yasuhiro et al. (2008) Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob Agents Chemother 52:2111-9
Azad, Nilofer S; Annunziata, Christina M; Steinberg, Seth M et al. (2008) Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 112:1726-32
Dahut, William L; Scripture, Charity; Posadas, Edwin et al. (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14:209-14
Tan, A R; Steinberg, S M; Parr, A L et al. (2008) Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol 19:185-90
Bishop, M R; Dean, R M; Steinberg, S M et al. (2008) Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 19:1935-40
Berna, Marc J; Annibale, Bruno; Marignani, Massimo et al. (2008) A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 93:1582-91
Lechleider, Robert J; Arlen, Philip M; Tsang, Kwong-Yok et al. (2008) Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 14:5284-91
Gregorc, V; Hidalgo, M; Spreafico, A et al. (2008) Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin Pharmacol Ther 83:477-84
Norton, Jeffrey A; Venzon, David J; Berna, Marc J et al. (2008) Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 247:501-10
Powell, Anathea C; Stratakis, Constantine A; Patronas, Nicholas J et al. (2008) Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery 143:750-8

Showing the most recent 10 out of 127 publications